Gastroenterology

Adding abemaciclib to hormonal therapy reduces recurrence in patients with HR+ HER2- early breast cancer




Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020.

Source link

Related posts

#BCSM; Guidance for Geriatric Assessment; Baking Soda and Leukemia

Newsemia

Review IDs Dietary Factors Linked to Lower CRC Incidence

Newsemia

Implementation of combined pediatric observation unit improves patient outcomes, satisfaction

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World